Rare Metabolic Causes of Low Bone Density

Low bone density, or osteopenia and osteoporosis, most often stems from age, hormone changes or common nutritional deficiencies. However, a handful of rare metabolic disorders can also weaken bones in unexpected ways. Recognizing these uncommon conditions early can help guide appropriate diagnosis and treatment.

---

1. Hypophosphatasia

Hypophosphatasia (HPP) is a genetic disorder caused by mutations in the ALPL gene, leading to low activity of tissue-nonspecific alkaline phosphatase. This enzyme is crucial for bone and tooth mineralization.

Key features:

• Early-onset skeletal pain, fractures or deformities
• Low serum alkaline phosphatase despite bone loss
• High levels of substrates such as pyridoxal-5′-phosphate (vitamin B₆) in blood
• Dental problems (premature tooth loss)

Diagnosis & management:

• Genetic testing for ALPL variants
• Enzyme replacement therapy (asfotase alfa) can improve bone density
• Supportive care (physical therapy, pain control, fracture management)

---

2. X-Linked Hypophosphatemia

X-linked hypophosphatemia (XLH) is the most common hereditary form of rickets, caused by mutations in the PHEX gene that increase levels of fibroblast growth factor 23 (FGF23). FGF23 reduces phosphate reabsorption in kidneys and lowers active vitamin D levels.

Key features:

• Bone pain, short stature, bowing of legs in children
• Persistent low serum phosphate and inappropriately normal or low vitamin D
• Normal calcium levels
• Dental abscesses

Diagnosis & management:

• Measure serum phosphate, 1,25-dihydroxyvitamin D and FGF23
• Conventional therapy with phosphate supplements and calcitriol
• Burosumab, an anti-FGF23 antibody, increases phosphate levels and improves bone mineralization

---

3. Homocystinuria

Homocystinuria, most often due to cystathionine β-synthase (CBS) deficiency, leads to elevated homocysteine and methionine levels. High homocysteine disrupts collagen cross-linking in bone matrix.

Key features:

• Marfanoid habitus, lens dislocation, thromboembolism
• Osteoporosis or osteopenia on bone density scans
• High plasma homocysteine and methionine
• Variable response to vitamin B₆ (pyridoxine) supplementation

Diagnosis & management:

• Newborn screening in many regions
• Plasma amino acid profile, genetic testing
• High-dose pyridoxine, folic acid, vitamin B₁₂ and dietary methionine restriction
• Antithrombotic prophylaxis if indicated

---

4. Wilson’s Disease

Wilson’s disease is an autosomal recessive disorder of copper metabolism caused by mutations in ATP7B. Copper accumulation in liver, brain and other tissues can impair bone remodeling.

Key features:

• Liver disease (hepatitis, cirrhosis), neurological symptoms (tremors, dystonia)
• Low bone density, sometimes without fractures
• Low ceruloplasmin, high urinary copper excretion
• Kayser-Fleischer rings on slit-lamp exam

Diagnosis & management:

• Serum ceruloplasmin, 24-hour urinary copper, genetic testing
• Chelation therapy (penicillamine, trientine) or zinc
• Monitor bone density; ensure adequate calcium and vitamin D

---

5. Gaucher Disease

Gaucher disease type I results from glucocerebrosidase deficiency, leading to lipid-laden macrophages (Gaucher cells) in liver, spleen and bone marrow.

Key features:

• Splenomegaly, hepatomegaly, cytopenias
• Bone pain, osteopenia, lytic lesions, “Erlenmeyer flask” deformity of femur
• Elevated chitotriosidase or glucosylsphingosine levels

Diagnosis & management:

• Enzyme assay for glucocerebrosidase activity
• Glucocerebrosidase replacement (imiglucerase, velaglucerase) or substrate reduction therapy (eliglustat)
• Physical therapy and analgesia for bone crises

---

6. Primary Hyperoxaluria

Primary hyperoxaluria (PH) encompasses three rare enzymatic defects causing excessive oxalate production, which can deposit in kidneys and bone.

Key features:

• Recurrent kidney stones, nephrocalcinosis, progressive renal failure
• Bone pain, fractures in advanced renal disease
• Elevated urinary and plasma oxalate

Diagnosis & management:

• Urinary oxalate measurement, genetic testing for AGXT, GRHPR or HOGA1 mutations
• High fluid intake, crystallization inhibitors (citrate)
• Vitamin B₆ in some PH1 patients
• Liver transplantation in severe cases to correct enzyme defect

---

7. Cystinosis

Cystinosis is a lysosomal storage disorder caused by CTNS gene mutations, leading to cystine accumulation in kidneys, eyes and other tissues.

Key features:

• Fanconi syndrome in infancy (renal tubular dysfunction)
• Rickets-like bone disease, growth failure
• Corneal cystine crystals

Diagnosis & management:

• Measurement of leukocyte cystine levels, genetic testing
• Cysteamine therapy to deplete cystine
• Support for renal function, electrolyte and vitamin D supplementation

---

8. Other Considerations

While far rarer than age-related or nutritional causes, these conditions share a common theme: altered metabolism disrupts bone remodeling or mineral balance. Additional disorders that may contribute include:

• Mitochondrial cytopathies
• Glycogen storage diseases
• Some mucopolysaccharidoses

If you or a loved one have unexplained bone pain, fractures or lab abnormalities, exploring rare metabolic causes can be crucial.

---

When to Seek Professional Guidance

If you experience persistent bone pain, unexplained fractures or lab tests suggesting electrolyte or enzyme imbalances, be proactive:

• Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker
• Share your results and concerns with a specialist in metabolic bone disease or genetics
• Always speak to a doctor about anything that could be life threatening or serious

Early diagnosis of a rare metabolic disorder can dramatically improve bone health and overall well-being.